You just read:

Pfizer's Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market

News provided by

Spherix Global Insights

Jul 31, 2018, 09:27 ET